title: [Dual regulation by delta opioid receptor agonists on the delayed rectified potassium channels in NG108-15 cells].
abstract: OBJECTIVE
  To investigate the dual effects by the delta opioid receptor agonists DPDPE on the delayed rectified potassium channels in NG108-15 cells.
  
  
  METHODS
  A series of outward currents were evoked in NG108-15 cells by depolarizing voltage from -50 mV to +80 mV at holding potential of -90 mV. These currents were delayed rectified potassium currents. Relatively selected delta opioid receptor agonists DPDPE of higher and lower concentrations were used to modulate the delayed rectified K+ current in NG108-15 cells. Opioid receptor antagonist Naloxone (NAL) and relatively selected delta opioid receptor antagonist Naltrindole (NTI) were used in the present experiments for the characterization of the actions of opioid receptors.
  
  
  RESULTS
  The relatively higher concentrations of delta opioid receptor agonist DPDPE (> or = 10(-6) mol/L) significantly increased the amplitude of the delayed rectified K+ current. On the contrary, the relatively lower concentrations of DPDPE (< or = 10(-12) mol/L) decreased the amplitude of the delayed rectified K+ current (P < 0.05). Furthermore both the increase and decrease were time-dependent.
  
  
  CONCLUSIONS
  delta opioid receptor agonist has dual regulatory effects on the delayed rectified potassium channels in NG108-15 cells.
authors.affiliation: Department of Pharmacology, Institute of Basic Medical Sciences, CAMS, PUMC, Beijing 100005, China. caiying_ye@sohu.com
authors.forename: Cai-ying
authors.initials: CY
authors.lastname: Ye
authors.forename: Qing-xia
authors.initials: QX
authors.lastname: Li
authors.forename: Xiao-li
authors.initials: XL
authors.lastname: Yu
authors.forename: Jing-jing
authors.initials: JJ
authors.lastname: Qi
authors.forename: Juan
authors.initials: J
authors.lastname: Li
authors.forename: De-chang
authors.initials: DC
authors.lastname: Zhang
mesh_terms: D000818:Animals; D002462:Cell Membrane / Q000378:metabolism; D020881:Enkephalin, D-Penicillamine (2,5)- / Q000494:pharmacology*; D005910:Glioma / Q000378:metabolism / Q000473:pathology; D006822:Hybrid Cells / Q000378:metabolism; D051379:Mice; D009270:Naloxone / Q000494:pharmacology; D009271:Naltrexone / Q000031:analogs & derivatives* / Q000494:pharmacology; D009447:Neuroblastoma / Q000378:metabolism / Q000473:pathology; D018408:Patch-Clamp Techniques; D024661:Potassium Channels, Inwardly Rectifying / Q000187:drug effects* / Q000378:metabolism; D051381:Rats; D017465:Receptors, Opioid, delta / Q000819:agonists*; D014407:Tumor Cells, Cultured
chemical_list: D024661:Potassium Channels, Inwardly Rectifying; D017465:Receptors, Opioid, delta; D009270:Naloxone; D009271:Naltrexone; D020881:Enkephalin, D-Penicillamine (2,5)-; C055382:naltrindole